Phase II trial of iboctadekin (rhIL-18) on a daily X 5 schedule in metastatic melanoma (MM).

J. M. Kirkwood, R. Kefford, T. Logan, P. N. Mainwaring, M. Millward, A. C. Pavlick, M. M. Dar, S. Kathman, K. Laubscher, W. Bell

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

Original languageEnglish
Article number10043
Pages (from-to)551S-551S
Number of pages1
JournalJournal of Clinical Oncology
Volume24
Issue number18
DOIs
Publication statusPublished - 20 Jun 2006
Externally publishedYes
Event42nd Annual Meeting of the American-Society-of-Clinical-Oncology - Atlanta, United States
Duration: 2 Jun 20066 Jun 2006

Cite this